Bridgeway Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Bridgeway Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-114,900	Closed	-$564K	–	1356
2021 Q3	$564K	Sell	114,900 -150,000	-57%	-$728K	0.01%	999
2021 Q2	$1.4M	Buy	264,900 +85,000	+47%	+$440K	0.03%	742
2021 Q1	$864K	Buy	179,900 +50,000	+38%	+$261K	0.02%	914
2020 Q4	$562K	Buy	129,900 +4,900	+4%	+$21K	0.01%	903
2020 Q3	$515K	Sell	125,000 -60,000	-32%	-$232K	0.01%	876
2020 Q2	$474K	Buy	185,000 +90,000	+95%	+$264K	0.01%	872
2020 Q1	$275K	Sell	95,000 -20,000	-17%	-$89.6K	0.01%	959
2019 Q4	$436K	Hold	115,000	–	–	0.01%	1038
2019 Q3	$588K	Hold	115,000	–	–	0.01%	884
2019 Q2	$713K	Sell	115,000 -30,000	-21%	-$173K	0.01%	859
2019 Q1	$1.03M	Buy	+145,000	New	+$1.3M	0.01%	756

Bridgeway Capital Management's ADMS Position: Q4 2021 in Review

Bridgeway Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 114,900 shares — an estimated $564K sold.

Bridgeway Capital Management first reported a position in ADMS in Q1 2019 and held it in 11 quarters. The position peaked at $1.4M in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Bridgeway Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Bridgeway Capital Management sold 114,900 Adamas Pharmaceuticals shares in Q4 2021, an estimated $564K.
Bridgeway Capital Management first reported a position in Adamas Pharmaceuticals in Q1 2019 and held it in 11 quarters.
Bridgeway Capital Management's Adamas Pharmaceuticals position peaked at $1.4M in Q2 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Bridgeway Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.